WaveMan
WaveMan · Company
ANIX · Anixa Biosciences Inc
> Search tickers & screens ⌘K
LIVE
← All companies

ANIX Anixa Biosciences (ANIX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000715446
Quote by TradingView
Cluster · 4 insidersC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $18.8K priced

What the filings say about ANIX

Insiders, 180 days
+$475.5K net bought
4 buyers

Anixa Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Anixa Biosciences Inc insiders bought a net $475.5K of stock across 70 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Titterton Lewis H jr
Director
BUY
2026-10-26 SECtraded 2026-10-23
8,000
$23.8K
n/a
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (32 buys), the last on Sep 23, 2026.
  • +5.3% median (+3.8% mean) 90-day return after 28 previous buys.
  • The trade is 0.8% of the 1,054,003 shares held after it.
  • 3 other insiders bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Titterton Lewis H jr bought about $23.8K of ANIX on Oct 23, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.
KUMAR AMIT
Chief Executive Officer
BUY
2026-10-22 SEC
8,000
$21.8K
+9.7%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (20 buys, 1 sale), the last on Sep 24, 2026.
  • +1.9% median (+2.4% mean) 90-day return after 15 previous buys.
  • The trade is 1.2% of the 680,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer KUMAR AMIT bought about $21.8K of ANIX on Oct 22, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.
Catelani Michael
President, COO, & CFO
BUY
2026-09-30 SEC
5,500
$15.6K
+18.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jan 15, 2025.
  • +25.0% median (+20.1% mean) 90-day return after 5 previous buys.
  • The trade is 11.0% of the 50,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, COO, & CFO Catelani Michael bought about $15.6K of ANIX on Sep 30, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.
Baskies Arnold M
Director
BUY
2026-09-28 SECtraded 2026-09-24
5,000
$13.8K
+15.1%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jan 28, 2026.
  • +1.9% median (+2.8% mean) 90-day return after 7 previous buys.
  • The trade is 3.6% of the 140,572 shares held after it.
  • 3 other insiders bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Baskies Arnold M bought about $13.8K of ANIX on Sep 24, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.
KUMAR AMIT
Chief Executive Officer
BUY
2026-09-28 SECtraded 2026-09-24
7,000
$19.5K
+15.1%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (19 buys, 1 sale), the last on Sep 10, 2026.
  • +1.9% median (+2.4% mean) 90-day return after 15 previous buys.
  • The trade is 1.0% of the 672,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer KUMAR AMIT bought about $19.5K of ANIX on Sep 24, 2026; 3 other insiders bought within 30 days and 27 funds added in the latest 13F quarter.
70 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 65 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$475.5K over 180 days
+$293.1K over 90 days
more than 84% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.1% of the float short (float per yahoo 2026-10-27) · 6.4 days to cover · settled 2026-10-15
more than 50% of Pharma & Biotech
What changed in the last 30 days
Oct 26Director Titterton Lewis H jr bought $23.8K (Oct 23)
Oct 22Chief Executive Officer KUMAR AMIT bought $21.8K (Oct 22)
Sep 30President, COO, & CFO Catelani Michael bought $15.6K (Sep 30)

Watch ANIX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-21.5%12M
-44%-21%+2%+25%2025-102025-122026-022026-042026-062026-082026-10 2026-09-23 · Titterton Lewis H jr bought $131.9K2026-06-12 · KUMAR AMIT bought $52.5K2026-07-20 · Titterton Lewis H jr bought $41.6K2026-01-28 · Baskies Arnold M bought $30.4K2026-09-10 · Titterton Lewis H jr bought $27.3K2026-10-23 · Titterton Lewis H jr bought $23.8K2026-10-22 · KUMAR AMIT bought $21.8K2026-09-24 · KUMAR AMIT bought $19.5K2026-07-31 · KUMAR AMIT bought $17.4K2026-07-20 · KUMAR AMIT bought $17.3K2026-07-27 · KUMAR AMIT bought $17.2K2026-09-30 · Catelani Michael bought $15.6K2026-07-10 · KUMAR AMIT bought $15.2K2026-09-10 · KUMAR AMIT bought $13.8K2026-09-24 · Baskies Arnold M bought $13.8K2026-07-24 · KUMAR AMIT bought $11.2K2026-07-27 · KUMAR AMIT bought $10.7K2026-07-15 · Titterton Lewis H jr bought $9.2K2026-09-10 · KUMAR AMIT bought $8.2K2026-06-16 · Titterton Lewis H jr bought $7.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANIX: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,329,852 sh
$3.7M
UBS Group AG
585,430 sh
$1.6M
Laird Norton Wetherby Trust Company, LLC
578,727 sh
$1.6M
D.A. DAVIDSON & CO.
539,272 sh
$1.5M
GEODE CAPITAL MANAGEMENT, LLC
359,194 sh
$1.0M

Congress trades in ANIX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANIX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ANIX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$301.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$20.2K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$451.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$990.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$65.1K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$59.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Kumar
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.5M
$3.7M
$1.3M
-26%
+37%
2024
$3.5M
$3.1M
$1.8M
-38%
+18%
2023
$3.6M
-$2.6M
$2.0M
-44%
-19%
2022
$2.2M
$4.8M
$1.8M
+17%
-34%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $475.5K bought by insiders over 180 days, 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANIX financials

Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$7.4M
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-66.8%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets
-63.4%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-75.9%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-6.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-102024-102023-102022-10
Revenuen/a$210.0K$210.0Kn/a
Operating income-$11.7M-$13.8M-$11.0M-$13.9M
Net income-$10.9M-$12.6M-$9.8M-$13.6M
EPS (diluted)-0.34-0.39-0.320.45
Operating cash flow-$7.2M-$7.3M-$6.2M-$6.5M
Cash$1.2M$1.3M$915.0K$12.4M
Buybacksn/a$6.0Kn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

ANIX Stock Sonar score 5/7 axes

Find similar shapesCompare

ANIX ranks highest on insider conviction (89th percentile) and risk and compliance (71st), and lowest on institutional and government (37th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
38
Inputs
  • Return on equity-66.8% · 44 pct, sector of 545
  • Return on assets-63.4% · 37 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-75.9% · 34 pct, sector of 576
Growth
44
Inputs
  • Revenue growth, YoY+0.0% · 44 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
89
Inputs
  • Net Form 4 buying (codes P and S), 180d$476K · 85 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
37
Inputs
  • Funds adding, latest quarter27 · 37 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
71
Inputs
  • Short interest, % of float+4.1% · 62 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.9% · 79 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANIX filings, in plain words

Are Anixa Biosciences insiders buying or selling ANIX?

In the 180 days to 2026-10-28, Anixa Biosciences insiders were net buyers, a net $475.5K across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-28, Anixa Biosciences insiders were net buyers of ANIX, a net $475.5K across purchases and sales reported on Form 4 by 4 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies